ATC code C02
ATC code C02 Antihypertensives is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup C02 is part of the anatomical group C Cardiovascular system.[4]
| ATC codes |
|---|
| C Cardiovascular system |
| C01 Cardiac therapy |
| C02 Antihypertensives |
| C03 Diuretics |
| C04 Peripheral vasodilators |
| C05 Vasoprotectives |
| C07 Beta blocking agents |
| C08 Calcium channel blockers |
| C09 Agents acting on the renin–angiotensin system |
| C10 Lipid modifying agents |
|
|
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC02.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
C02A Antiadrenergic agents, centrally acting
C02AA Rauvolfia alkaloids
- C02AA01 Rescinnamine
- C02AA02 Reserpine
- C02AA03 Combinations of rauwolfia alkaloids
- C02AA04 Rauwolfia alkaloids, whole root
- C02AA05 Deserpidine
- C02AA06 Methoserpidine
- C02AA07 Bietaserpine
- C02AA52 Reserpine, combinations
- C02AA53 Combinations of rauwolfia alkaloids, combinations
- C02AA57 Bietaserpine, combinations
C02AB Methyldopa
- C02AB01 Methyldopa (levorotatory)
- C02AB02 Methyldopa (racemic)
C02AC Imidazoline receptor agonists
- C02AC01 Clonidine
- C02AC02 Guanfacine
- C02AC04 Tolonidine
- C02AC05 Moxonidine
- C02AC06 Rilmenidine
C02B Antiadrenergic agents, ganglion-blocking
C02BA Sulfonium derivatives
- C02BA01 Trimetaphan
C02BB Secondary and tertiary amines
- C02BB01 Mecamylamine
C02C Antiadrenergic agents, peripherally acting
C02CA Alpha-adrenoreceptor antagonists
- C02CA01 Prazosin
- C02CA02 Indoramin
- C02CA03 Trimazosin
- C02CA04 Doxazosin
- C02CA06 Urapidil
C02CC Guanidine derivatives
- C02CC01 Betanidine
- C02CC02 Guanethidine
- C02CC03 Guanoxan
- C02CC04 Debrisoquine
- C02CC05 Guanoclor
- C02CC06 Guanazodine
- C02CC07 Guanoxabenz
C02D Arteriolar smooth muscle, agents acting on
C02DB Hydrazinophthalazine derivatives
- C02DB01 Dihydralazine
- C02DB02 Hydralazine
- C02DB03 Endralazine
- C02DB04 Cadralazine
C02DC Pyrimidine derivatives
- C02DC01 Minoxidil
C02DD Nitroferricyanide derivatives
- C02DD01 Nitroprusside
C02DG Guanidine derivatives
- C02DG01 Pinacidil
C02K Other antihypertensives
C02KA Alkaloids, excluding rauwolfia
- C02KA01 Veratrum
C02KB Tyrosine hydroxylase inhibitors
- C02KB01 Metirosine
C02KC MAO inhibitors
- C02KC01 Pargyline
C02KD Serotonin antagonists
- C02KD01 Ketanserin
C02KX Antihypertensives for pulmonary arterial hypertension
- C02KX01 Bosentan
- C02KX02 Ambrisentan
- C02KX03 Sitaxentan
- C02KX04 Macitentan
- C02KX05 Riociguat
- C02KX52 Ambrisentan and tadalafil
C02L Antihypertensives and diuretics in combination
C02LA Rauwolfia alkaloids and diuretics in combination
- C02LA01 Reserpine and diuretics
- C02LA02 Rescinnamine and diuretics
- C02LA03 Deserpidine and diuretics
- C02LA04 Methoserpidine and diuretics
- C02LA07 Bietaserpine and diuretics
- C02LA08 Rauwolfia alkaloids, whole root and diuretics
- C02LA09 Syrosingopine and diuretics
- C02LA50 Combinations of rauwolfia alkaloids and diuretics including other combinations
- C02LA51 Reserpine and diuretics, combinations with other drugs
- C02LA52 Rescinnamine and diuretics, combinations with other drugs
- C02LA71 Reserpine and diuretics, combinations with psycholeptics
C02LB Methyldopa and diuretics in combination
- C02LB01 Methyldopa (levorotatory) and diuretics
C02LC Imidazoline receptor agonists in combination with diuretics
- C02LC01 Clonidine and diuretics
- C02LC05 Moxonidine and diuretics
- C02LC51 Clonidine and diuretics, combinations with other drugs
C02LE Alpha-adrenoreceptor antagonists and diuretics
- C02LE01 Prazosin and diuretics
C02LF Guanidine derivatives and diuretics
- C02LF01 Guanethidine and diuretics
C02LG Hydrazinophthalazine derivatives and diuretics
- C02LG01 Dihydralazine and diuretics
- C02LG02 Hydralazine and diuretics
- C02LG03 Picodralazine and diuretics
- C02LG51 Dihydralazine and diuretics, combinations with other drugs
- C02LG73 Picodralazine and diuretics, combinations with psycholeptics
C02LK Alkaloids, excluding rauwolfia, in combination with diuretics
- C02LK01 Veratrum and diuretics
C02LL MAO inhibitors and diuretics
- C02LL01 Pargyline and diuretics
C02LX Other antihypertensives and diuretics
- C02LX01 Pinacidil and diuretics
C02N Combinations of antihypertensives in ATC-group C02
- Empty group
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code C02". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QC02". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.